Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy Trial

"The intervention in this study, Nebulized MSC-exos for Anti-MDA5+ RP-ILD Treatment, is distinguished by its use of mesenchymal stem cell-derived exosomes (MSC-exos) for direct pulmonary delivery via nebulization. This targeted approach aims to modulate immune responses and reduce inflammation specific to lung diseases, offering a novel therapeutic strategy. This method stands out for its potential to provide a safer and more effective treatment for RP-ILD compared to traditional therapies."